Compared to Estimates, Allbirds, Inc. (BIRD) Q4 Earnings: A Look at Key Metrics

Allbirds, Inc. (BIRD) reported $71.99 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 14.5%. EPS of -$0.25 for the same period compares to -$0.15 a year ago.

The reported revenue represents a surprise of +4.52% over the Zacks Consensus Estimate of $68.88 million. With the consensus EPS estimate being -$0.22, the EPS surprise was -13.64%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Allbirds, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Stores: 60 compared to the 60 average estimate based on three analysts.
  • Store - United States: 45 versus 45 estimated by two analysts on average.
  • Store - International: 15 versus the two-analyst average estimate of 15.
  • Net Revenue- International: $16.19 million compared to the $14.62 million average estimate based on four analysts. The reported number represents a change of -12.9% year over year.
  • Net Revenue- United States: $55.80 million versus the four-analyst average estimate of $54.52 million. The reported number represents a year-over-year change of -14.9%.
View all Key Company Metrics for Allbirds, Inc. here>>>

Shares of Allbirds, Inc. have returned -20.2% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.

It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Allbirds, Inc. (BIRD) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.